GE HealthCare Q2 2026: EPS beat, orders up 11.1%, margin slips, guidance held
GE HealthCare beat on earnings but not on profitability: adjusted EPS of $1.13 topped the $1.0558 consensus while adjusted EBIT margin slipped to 14.2%. Orders grew 11.1% organically and full-year guidance was reaffirmed, yet Patient Care Solutions is still shrinking. The view is Neutral — a solid commercial quarter wrapped around a softer underlying margin story.
1 · Expected vs. Actual
Free preview belowDiluted EPS of $1.24 rose 16.5% from $1.06, and adjusted EPS of $1.13 rose 6.6%, ahead of the $1.0558 consensus. Adjusted EBIT of $750 million grew only 2.9%, with margin down 40 basis points to 14.2%. Tariff refunds did heavy lifting: $129 million of the net income came from IEEPA refunds, and $106 million of refunds tied to 2025 tariffs was stripped out of adjusted results.
Revenue rose 5.7% to $5.295 billion from $5.007 billion, but organic growth was only 3.5%, so currency and acquisitions did part of the work. Advanced Imaging Solutions grew 7.9% and Pharmaceutical Diagnostics grew 15.6%, while Patient Care Solutions fell 13.3%. Product sales of $3.416 billion and service sales of $1.878 billion both moved higher.
Log in to read 35 analyses a week for free
Create a free account to read 35 full earnings analyses each week — all five steps: expected vs. actual, guidance tracker, money flow, balance sheet and risks. Members get unlimited access.
Figures on this page come from the company's original SEC filings. The analysis is generated automatically and checked against validation rules, but may still contain errors or omissions. Not investment advice. · Generated 2026-09-17
Answers are based on the earnings release and the analysis above. Free accounts get 3 questions a week; members get 30 a day.